These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32643874)

  • 1. COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network.
    Kario K; Morisawa Y; Sukonthasarn A; Turana Y; Chia YC; Park S; Wang TD; Chen CH; Tay JC; Li Y; Wang JG;
    J Clin Hypertens (Greenwich); 2020 Jul; 22(7):1109-1119. PubMed ID: 32643874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19.
    Shah H; Khan MSH; Dhurandhar NV; Hegde V
    Acta Diabetol; 2021 Jul; 58(7):831-843. PubMed ID: 33587177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
    Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
    J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
    Edmonston DL; South AM; Sparks MA; Cohen JB
    Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
    Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.
    Savoia C; Volpe M; Kreutz R
    Circ Res; 2021 Apr; 128(7):1062-1079. PubMed ID: 33793331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
    Dworakowska D; Grossman AB
    J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.
    Vila-Corcoles A; Satue-Gracia E; Ochoa-Gondar O; Torrente-Fraga C; Gomez-Bertomeu F; Vila-Rovira A; Hospital-Guardiola I; de Diego-Cabanes C; Bejarano-Romero F; Rovira-Veciana D; Basora-Gallisa J
    J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1379-1388. PubMed ID: 32710674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
    Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
    Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delineating clinical characteristics and comorbidities among 206 COVID-19 deceased patients in India: Emerging significance of renin angiotensin system derangement.
    Majeed J; Ajmera P; Goyal RK
    Diabetes Res Clin Pract; 2020 Sep; 167():108349. PubMed ID: 32712124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension and COVID-19: Current Evidence and Perspectives.
    Gallo G; Calvez V; Savoia C
    High Blood Press Cardiovasc Prev; 2022 Mar; 29(2):115-123. PubMed ID: 35184271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
    Terano C; Ishikura K; Miura M; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Ando T; Honda M
    Eur J Pediatr; 2016 May; 175(5):631-7. PubMed ID: 26687571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
    Tadic M; Cuspidi C
    J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351
    [No Abstract]   [Full Text] [Related]  

  • 18. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
    Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
    Cadegiani FA; Goren A; Wambier CG
    Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension.
    Mancusi C; Grassi G; Borghi C; Carugo S; Fallo F; Ferri C; Giannattasio C; Grassi D; Letizia C; Minuz P; Muiesan ML; Perlini S; Pucci G; Rizzoni D; Salvetti M; Sarzani R; Sechi L; Veglio F; Volpe M; Iaccarino G;
    J Hypertens; 2021 Feb; 39(2):376-380. PubMed ID: 33186327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.